How to Choose Among Similar CAR-T Therapies?

Currently, there are multiple CAR-T products targeting the same antigen available on the market, which can make it difficult for patients to decide which one to choose.

Experts recommend selecting a therapy based on the treatment target. It is generally advisable to prioritize approved products, as they have been validated, providing better assurance of safety and efficacy. For example, CD19-targeting CAR-T products are typically preferred over CD22-targeting ones, and BCMA-targeting therapies are favored over GPRC5D-targeting ones.

Additionally, it’s important to consider the origin of the CAR-T cells (such as human-derived vs. mouse-derived) and the costimulatory signals used (e.g., 4-1BB vs. CD28). Different conditions may also influence the choice; for instance, lymphoma patients may be more suitable for CD28, while those with acute leukemia might benefit more from 4-1BB.

In the end, patients are advised to make an informed decision based on their medical history and the guidance of their doctors.